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Abstract
Background: Not only is glutamine deficiency an independent predictor of mortality in intensive care unit (ICU)
patients, but glutamine supplementation is also recommended for its proven outcome benefits. However, recent data
suggest that early glutamine supplementation in certain patient groups increase mortality. The aim of this study was to
investigate plasma glutamine levels of adult ICU patients in the South African setting and to determine relationships
between glutamine levels, gender, diagnostic categories and selected inflammatory markers. The data from this study
will be used as baseline measurement to support a large scale study that will be undertaken in the South African ICU
population.
Methods: This cross-sectional, analytical study included 60 mixed adult ICU patients within 24 h post ICU admission.
Plasma glutamine levels were determined on admission. The relationship between glutamine levels, Interleukin-6 (IL-6)
and C-reactive protein (CRP); as well as gender- and diagnosis-related differences in glutamine levels were also
investigated. A non-parametric ROC curve was computed to determine the CRP concentration cut-off point above
which glutamine becomes deficient.
Results: The median plasma glutamine level (497 μmol/L) was in the normal range; however, 38.3 % (n= 23) of patients
had deficient (<420 μmol/L) and 6.7 % (n = 4) had supra-normal glutamine levels (>930 μmol/L). No significant difference
could be detected between glutamine levels and gender or diagnosis categories as a group. When only the medical and
surgical categories were compared, the median plasma glutamine level of the medical patients were significantly lower
than that of the surgical patients (p = 0.042). Glutamine showed inverse associations with CRP levels (r = −0.44, p < 0.05)
and IL-6 concentrations (r = −0.23, p = 0.08). A CRP cut-off value of 95.5 mg/L was determined above which glutamine
levels became deficient.
Conclusions: About a third of patients (38 %) were glutamine deficient on admission to ICU, whereas some presented
with supra-normal levels. While glutamine levels correlated inversely with inflammatory markers, and a CRP value of above
95.5 mg/L indicated potential glutamine deficiency, the clinical application of this finding needs further investigation.
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Background
Pharmaconutrition refers to nutrients that are adminis-
tered as pharmacological agents, forming part of the
medical treatment plan. It is currently applied in various
clinical settings to improve patient outcomes [1]. Glu-
tamine, the most abundant non-essential amino acid, is
the most-researched pharmaconutrient to date [2]. Pre-
vious studies showed decreased levels of plasma and
muscle glutamine in selected critically ill, post-surgical,
multiple trauma, burns, septic and general intensive care
unit (ICU) patients [3–5], resulting in the classification
of glutamine as a “conditionally essential amino acid”
under certain circumstances. Glutamine deficiency and,
therefore, its unavailability to perform important func-
tions contributes to an inappropriate response to stress
and injury, ultimately leading to an increased ICU and
post-ICU mortality risk.
Glutamine supplementation has been extensively stud-
ied for its contribution to the improvement of patient
outcomes. Until recently, it has been deemed safe and
effective in a variety of patient groups, including the
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severely ill, burns and surgical patient [6–9]. Outcome
benefits such as reductions in length of hospital stay
(LOHS), length of ICU stay, mortality risk and infectious
complications, as well as an improvement in nitrogen
balance, was previously reported, depending on the spe-
cific patient group as well as the dose and route of ad-
ministration [6–9].
The Reducing Deaths due to Oxidative Stress (REDOXS)
study questioned the safety and applicability of glutamine
supplementation in all patient groups. In this study an in-
creased mortality risk was found when supplementing mul-
tiple organ failure (MOF) patients with high dosages of
enteral and parenteral glutamine within 24 h after ICU ad-
mission [10]. In a sub-sample of this study only 31 % of pa-
tients were glutamine deficient (<420 μmol/L) while 15 %
had supra-normal levels (>930 μmol/L). Moreover, Rodas
et al. [11] found that a U-shaped curve represents the asso-
ciation between glutamine and mortality, where both low
(<420 μmol/L) and high (>930 μmol/L) levels were associ-
ated with a higher mortality risk.
It is, therefore, important to determine the glutamine
status of patients in order to determine those requiring
supplementation and those where supplementation may
cause harm. In order to do this, it would be ideal to
measure plasma glutamine levels of all patients prior to
supplementation, but it is not routine practice in most
clinical settings. Furthermore, no South African (SA)
based data are available on plasma glutamine levels in
the ICU setting. Consequently, identifying markers,
which could aid in detecting patients in need of glutam-
ine supplementation or those where glutamine is contra-
indicated, has become a priority. The main aim of this
study, was to examine plasma glutamine levels of SA
adult ICU patients on day one of admission. In addition,
the influences of gender and different diagnostic categor-
ies on glutamine status were investigated. Previously a
relationship between inflammation and glutamine levels
has been reported. More specifically, an inverse associ-
ation between interleukin-6 (IL-6) and glutamine were
established [12, 13]. This is also the case for the inflam-
matory marker C-reactive protein (CRP) and amino
acids [14]. Therefore, the relationship between glutamine
levels and selected inflammatory markers, CRP and IL-6,
were investigated to confirm earlier findings on IL-6 and
to determine whether a relationship with CRP exist. The
findings of this research study will be used as baseline
data for a larger SA based study conducted in 2016.
Methods
Study design and setting
This observational cross-sectional study was performed
at two ICU settings in the North West province, SA.
The units are both mixed ICUs, consisting predomin-
antly of medical patients, but also admitting surgery and
trauma patients. The study was carried out in accord-
ance with the declaration of Helsinki and ethical ap-
proval was obtained from the North-West University
Human Research Ethics Committee (NWU-00186-13-
S1); the Policy, planning, research monitoring and evalu-
ation committee of the North West Department of
Health; and the Patient Safety Groups of both hospitals.
Informed, voluntary consent to participate in the study
was obtained from all participants or their legal proxy.
Patients
All adult patients (>18 years) admitted to the ICUs of
the two participating hospitals during the study period
(March to August, 2014) were eligible for inclusion, pro-
vided they met the following criteria: informed consent
obtained and blood sampling conducted within 24 h
post-ICU admission. Patients excluded were those re-
ceiving total parenteral nutrition with added glutamine
prior to blood sampling; those receiving glutamine-
enriched enteral feeding, high protein or amino acid-
based oral supplements prior to blood sampling; and
those who were pregnant or lactating. From the admis-
sion records of the hospital, a dropout analysis was per-
formed to identify the characteristics of the patients
admitted to the ICU during the study period, but not in-
cluded in the study.
Blood sampling and laboratory analysis
Venous blood samples were taken within 24 h following
ICU admission. Plasma samples for glutamine and IL-6
analysis were collected in ethylene diamine tetra-acetic
acid (EDTA) tubes and centrifuged within 30 min at
3000 × g for 15 min (4 °C). Plasma was then stored at –
80 °C within one hour post-sampling and for no longer
than 30 days, pending analysis. Plasma glutamine levels
were determined by an adapted method of the EZ:faast
amino acid analysis procedure (Phenomenex, Torrance,
CA, USA) for the analysis of free physiological amino
acids, using gas chromatography–mass spectrometry
(Hewlett Packard HP 6890 series Gas Chromatography
system, Palo Alto, CA, USA and Agilent 5973 N Mass
Selective Detector, Santa Clara, CA, USA). Plasma glu-
tamine levels of below 420 μmol/L were classified as de-
ficient and above 930 μmol/L as supra-normal [11, 15].
IL-6 was measured by means of the IL-6 Quantikine
enzyme-linked immunosorbent assay (ELISA) kit (R&D
systems, Minneapolis, MN, USA), using the Thermo-
fisher Scientific Multiskan FC (Vanta, Finland). For the
purpose of this research, IL-6 levels below 10 pg/mL
were regarded as normal [16].
For the determination of CRP concentrations, serum
gel tubes were prepared for analysis by centrifuging sam-
ples at 4000 rpm for 20 min. Analysis was conducted by
means of the Sequential Multiple Analyser Computer,
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using the Beckman Coulter DxC880i (Beckman Coulter,
Ireland). A reference CRP concentration of below 5 mg/
L was regarded as normal, whereas mild inflammation,
active and severe infection were classified according to
10–49 mg/L, 50–200 mg/L and >200 mg/L respectively
[17, 18].
Statistical analysis
The computer software package IBM SPSS® Statistics 22
(Statistical Package for Social Sciences, IBM, NY, USA)
was used for statistical analysis. A p-value of ≤0.05 was
considered statistically significant. Non-parametric data
were log-transformed to improve normality and are re-
ported as geometric means and 95 % confidence interval
(CI). Normally distributed data are reported as means
(95 % CI), and data that are still non-parametric follow-
ing log transformation, as medians [25th-75thpercentiles].
A Mann–Whitney U test were used to compare the me-
dian plasma glutamine level difference between genders.
The influence of different diagnoses on plasma glu-
tamine levels was examined by using the Kruskal-Wallis
analysis of variance (ANOVA) with the Bonferroni ad-
justment. In order to determine the relationship between
plasma glutamine levels and inflammatory markers, the
Spearman rank test was used. Other variables that could
influence the levels of plasma glutamine, were included
in the statistical models using analysis of covariance
(ANCOVA). A receiver operating characteristic (ROC)
curve was computed to determine the CRP cut-off value
at which glutamine becomes deficient.
Results
During the study period 60 ICU patients were included
in this study. The baseline characteristics of the patients
are presented in Table 1.
In Table 2, the median plasma glutamine levels of dif-
ferent medical condition categories are presented, to-
gether with the distribution of patients among deficient
(<420 μmol/L), normal (420-930 μmol/L), or supra-
normal (>930 μmol/L) levels in each category.
Of the patients 38.3 % were glutamine deficient, while
6.7 % had supra-normal levels. A non-significant differ-
ence was found comparing the median plasma glutamine
levels of female and male patients (p = 0.116), and be-
tween the different diagnostic categories (medical, sur-
gery, trauma) (Table 2). The inability to demonstrate a
difference between the groups was possibly related to
the statistical power, as very few trauma patients were
admitted to the ICUs during the study period. However
when excluding the two trauma patients, a significantly
lower median glutamine level was found in the medical
patient group compared to the surgical group (p = 0.042)
(after adjusting for age). Of the 42 medical patients in-
cluded, 42.8 % had deficient plasma glutamine levels,
whereas this was true for only 25 % of the surgical group
(Table 2). One patient in the medical group and three of
the patients admitted for surgical reasons had supra-
normal plasma glutamine levels. Table 2 elaborates on
these conditions.
Additionally, the association between plasma glutam-
ine levels and inflammatory markers (CRP and/or IL-6
levels) was investigated. A trend towards an inverse as-
sociation could be found between plasma glutamine
levels and IL-6 (r = −0.23, p = 0.08) (Fig. 1). After adjust-
ing for age by means of a partial correlation, the correl-
ation remained insignificant. However, a significant
inverse association was demonstrated between CRP and
plasma glutamine levels (r = −0.44, p < 0.05) (Fig. 2).
A non-parametric ROC curve was computed to deter-
mine the CRP level cut-off point at which plasma glu-
tamine levels became deficient (Fig. 3). The optimal cut-
off was obtained from the Youden index value at
95.5 mg/L [Sp (Specificity) = 69 %, Sn (Sensitivity) =
62.2 %, AUC (area under the curve): 0.759 (95 % CI
0.653; 0.865), p < 0.0001]. Of the patients that had CRP
values above 95.5 mg/L (n = 25), 74 % had plasma glu-
tamine levels below 420 μmol/L.
Table 1 Baseline characteristics of the ICU patient group
Characteristic ICU patients
Age, yeara 46 (32.3; 57.8)
n %
Gender:
Female 25 41.7
Male 35 58.3
ICU admission category:
Medical 43 71.7
Surgeryb 15 25.0
Trauma 2 3.3
Reason for ICU admission:
Cardiovascular/vascular 10 16.7
DKA/HONK 13 21.7
Gastrointestinal disorder 5 8.3
Liver failure 1 1.7
Neurological disorder 2 3.3
Post-surgery 9 15.0
Respiratory disorder 9 15.0
Renal failure 2 3.3
Septic shock 3 5.0
Trauma 2 3.3
Other 4 6.7
DKA diabetic ketoacidosis, HONK hyperosmolar non-ketotic coma, ICU intensive
care unit, n number/ frequency
aAge reported as mean (95 % CI)
bSurgery patients include: neurosurgery (n = 3), elective surgery (n = 4) and
emergency surgery (n = 8) patients
Nienaber et al. Nutrition Journal  (2016) 15:73 Page 3 of 9
The IL-6 and CRP values were also categorised to
present the plasma glutamine levels visually in different
categories of inflammation (Figs. 4 and 5). It was evident
that the majority of patients with normal IL-6 levels
(<10 pg/mL), i.e., without inflammation, also had normal
plasma glutamine levels. On the other hand, those with
inflammation presented with lower plasma glutamine
levels, especially those in the 150–500 pg/mL IL-6 and
50–200 mg/L CRP groups. In the hyper-inflammatory
groups (IL-6 > 500 pg/mL and CRP >200 mg/L) the glu-
tamine levels were scattered, ranging from very high to
very low plasma glutamine levels.
Discussion
This study aimed to establish the plasma glutamine
levels in a group of mixed ICU patients. It is important
as the measurement of glutamine levels is currently not
readily available, expensive and impractical in most hos-
pital settings. This research serves as a pilot study for a
larger study to be conducted in the SA setting, which
will further elaborate on plasma glutamine levels
throughout ICU stay, taking into account severity of ill-
ness as well as nutritional status of the patients. In order
to obtain a representative sample of a real-life ICU
population, all patients admitted to the chosen ICUs
during the study period were eligible for inclusion.
The median plasma glutamine level of this ICU popula-
tion (497 μmol/L [387–644 μmol/L]) was in the normal
range, with 38.2 % categorised as glutamine deficient. This
is comparable with findings by Oudemans-van Straaten
et al. [15], indicating a median ICU admission level of
495 μmol/L (interquartile range 350–600 μmol/L) to-
gether with other research reporting that 31 to 43 % of
ICU patients had deficient glutamine levels on day one of
ICU admission [11, 15, 19].
The mechanism whereby glutamine becomes depleted
is attributed to its translocation from the muscle to sup-
ply increased utilisation rates by vital splanchnic organs
Table 2 Glutamine status of the study population
Group Median plasma GLN level (μmol/L)
medians [25th – 75th percentiles]
P-value Deficient:
<420 μmol/L
Normal:
420 – 930 μmol/L
Supra-normal:
>930 μmol/L
n (%)
ICU patients (n = 60) 497 [387 – 644] 23 (38.3) 33 (55.0) 4 (6.70)
ICU men (n = 35) 558 [395 – 697] 0.116 12 (34.3) 19 (54.3) 4 (11.4)
ICU women (n = 25) 466 [380 – 543] 11 (44.0) 14 (56.0) –
Admission categories:
Medical (n = 42) 475 [372 – 627] 0.325** 18 (42.8) 23 (54.8) 1 (2.40)
Surgical (n = 16) 515 [468 – 782] 4 (25.0) 9 (56.2) 3 (18.8)
Trauma (n = 2) 432 [381 – 432] 1 (50.0) 1 (50.0) –
Specific conditions:b
HIV+ (n = 8) 562 [375 – 1062] 2 (25.0) 5 (62.5) 1 (12.5)
Liver failure (n = 4) 497 [389 – 643] 2 (50.0) 1 (25.0) 1 (25.0)
Renal failurea (n = 7) 575 [388 – 714] 3 (42.9) 4 (57.1) –
MOF (n = 4) 355 [310 – 689] 3 (75.0) 1 (25.0) –
Sepsis (n = 4) 355 [310 – 689] 3 (75.0) 1 (25.0) –
DM (n = 19) 380 [273 – 500] 10 (52.6) 9 (47.4) –
Non-parametric data reported as median [25th–75thpercentile]
DM diabetes mellitus, GLN glutamine, HIV+ human immunodeficiency virus seroreactive, ICU intensive care unit, MOF multiple-organ failure, n number/ frequency
aPatients not dialysed; bMedian plasma glutamine levels and distribution for certain conditions, that are expected to alter glutamine status
**p-value 0.042 when excluding trauma patients and comparing the medical and surgical patients
Fig. 1 Relationship between plasma glutamine and interleukin-6 levels
(r = −0.23, p = 0.08)
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[20]. Finally, de novo synthesis may decrease and be in-
sufficient to meet increased demands, resulting in glu-
tamine depletion [20–22]. Low plasma glutamine levels
are possibly life threatening, as they reflect the unavail-
ability of glutamine to fulfil its important functions. In
addition, deficient admission plasma glutamine levels are
an independent predictor of increased ICU and post-
ICU mortality rates [11, 15].
Supplementing patients who are not glutamine defi-
cient may pose a risk, as Rodas et al. [11] reported a U-
shaped curve association between plasma glutamine
levels and mortality. In this study, only 6.7 % of patients
had supra-normal plasma glutamine levels. Similarly,
Heyland et al. [19] reported supra-normal admission
levels in 15 % of MOF, ICU patients. Other studies also
found high levels in selected patients [11, 15]. Both
modest and very high plasma glutamine levels are attrib-
uted to organ failures, such as renal and acute liver fail-
ure [11, 23–25]. In this study group, however, only one
of the acute liver failure patients had a glutamine level
above 930 μmol/L. Nevertheless, the two other liver fail-
ure patients had chronic liver failure, which is thought
to rather lead to glutamine deficiency.
When considering diagnostic categories, it was difficult
to distinguish differences between the glutamine statuses.
In a recent study it was found that 60 % of trauma ICU
patients presented with deficient plasma glutamine levels
prior to glutamine supplementation [5]. In the current
study no conclusion could be drawn as to how trauma, as
primary diagnosis, influenced glutamine levels, due to the
few trauma patients included. Almost half of those admit-
ted for medical reasons had deficient levels on ICU admis-
sion. They also had significantly lower glutamine levels
than surgical patients. Diabetes, was previously thought
not to influence glutamine status [26, 27]. Interestingly,
however, when investigating the patients admitted for
medical reasons in further detail, the majority of diabetic
patients had deficient admission levels. On the other hand
some of the included patients with renal-, liver, MOF and
sepsis, as determined by clinical history, physical findings
and blood cultures, had deficient and normal glutamine
levels, contrary to previous reports of elevated levels to be
expected in these patients [19, 28].
Earlier research suggested that a positive HIV status
cause reduced plasma glutamine levels due to secondary
infections and an increased need to maintain immune
balance [29]. Findings in the current study showed that
HIV reactive patients predominantly had normal glu-
tamine levels. This could be ascribed to the fact that the
inflammatory response of the HIV positive patients in
this study were lower than expected, since there were no
statistically significant difference between HIV positive
and negative individuals with regard to either CRP (p =
0.271) or IL-6 levels (p = 0.654). It should be mentioned
Fig. 2 Relationship between plasma glutamine and CRP levels (r = −0.44, p < 0.05). CRP, C-reactive protein
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Fig. 4 Plasma glutamine levels presented per interleukin-6 category. The area between the dashed lines represents normal plasma glutamine reference
ranges. GLN, glutamine; IL-6, interleukin-6
Fig. 3 The receiver operating characteristic curve, computing the C-reactive protein level above which glutamine becomes deficient. Area under
curve (AUC): 0.759 (95 % CI 0.653; 0.865, p < 0.0001)
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that HIV status was not tested, but only recorded if
already diagnosed, and the disease progression was not
documented. Nevertheless, this was not the typical glu-
tamine profile that one would expect.
Regarding post-surgery patients, reduced plasma glu-
tamine levels have been well established as a characteris-
tic of their amino acid profile [3, 30, 31]. In the current
study, more than half of the surgery patients presented
with normal glutamine levels. However, the degree to
which levels are affected may be related to the severity,
complexity, and duration of the surgery, which was not
within the scope of this study [31]. These findings stress
the difficulty to make assumptions on glutamine status
based only on the patient’s diagnosis.
Other factors that may have influenced plasma glu-
tamine levels were also considered. In earlier studies,
plasma glutamine levels were found to be significantly
associated with gender in healthy individuals [32]. How-
ever in this study no significant gender-related difference
could be detected in the glutamine levels of patients. It
confirms findings by Viggiano et al. [31], who similarly
reported gender not to influence glutamine levels post-
operatively.
The current research further indicates, in support of
previous findings, that a definite relationship between
plasma glutamine and inflammation exists. Two well-
known inflammatory markers, IL-6 and CRP, were
measured. IL-6, described as an early marker of inflamma-
tion, drives inflammation, causing the release of CRP and
other markers of the acute-phase response. It is also a
predictor of the severity of the injury and major
complications [33]. A trend towards an inverse association
was found between plasma glutamine and IL-6 levels. This
is supported by earlier studies reporting a negative associ-
ation between IL-6 and glutamine [12, 13].
CRP is an inflammatory marker frequently measured
in the hospital setting. Suliman et al. [14] reported an in-
verse association between CRP and amino acids. Paren-
teral glutamine supplementation has further been found
to significantly reduce CRP concentrations [34, 35]. In
the current study an inverse association was found be-
tween CRP and glutamine levels (p < 0.05). A cut-off
point of 95.5 mg/L was determined as the CRP value
above which glutamine levels can potentially be expected
to become deficient. This is a novel finding and can pos-
sibly be used in the identification of patients at risk for
glutamine deficiency. When interpreting the plasma glu-
tamine levels grouped per category of CRP values, it is
clear that the lower glutamine levels are evident in pa-
tients with CRP levels that fall in the 50 to 200 mg/L
CRP value group (Fig. 5). However, those with CRP
values above 200 mg/L presented with a different profile,
since a range of plasma glutamine levels could be found
in this group (Fig. 5). This again shows that it is difficult
to predict patients that present with deficient plasma
glutamine levels by employing single biomarkers alone,
due to the high variability within ICU patient groups. It
could be postulated that those with the highest CRP
values, have more co-morbidities and hence the pres-
ence of MOF amongst this group is a reality. The latter
situation is regarded as a contra-indication for glutamine
supplementation [10, 36]. Again the number of samples
Fig. 5 Plasma glutamine levels presented per C-reactive protein category. The area between the dashed lines represents normal plasma glutamine
reference ranges. GLN, glutamine; CRP, C-reactive protein
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analysed in this study may be too small to draw any firm
conclusions on the exact CRP cut-off value, and the in-
clusion of more samples in future studies may provide
clear-cut results.
This study had certain limitations. As an observational
study, its results reflect only the population included in
the study and cannot be extrapolated to all ICU settings.
Together with this, calculating the patient’s severity of
illness scores are not routinely done in the participating
hospitals and could, therefore, not be reported. Body
composition measurements were not taken into account
in the interpretation of data. Furthermore, as the main
aim of the study was to determine plasma glutamine
levels on admission to the ICU, glutamine determination
was measured only once. A recent study reported that
low glutamine levels later during ICU stay correlated
with infection rates, length of ICU stay and LOHS [5].
Determination of plasma glutamine during the course of
the ICU stay might, therefore, yield better prognostic re-
sults and needs to be investigated further.
Conclusion
This study found glutamine deficiency in 38 % of
patients in a mixed ICU. Medical patients had signifi-
cantly lower plasma glutamine levels, but no gender-
related differences could be found. A significant
inverse association was found between plasma glu-
tamine and CRP levels, with a cut-off CRP value of
95.5 mg/L above which glutamine levels may become
deficient. Whether this can be translated into a clin-
ical recommendation regarding the use of CRP as
proxy marker in the determination of the need for
glutamine supplementation, is questionable and a lar-
ger sample size may be required to better conclude
on this. These results, therefore, support earlier find-
ings, which refuted a one-size-fits-all approach with
glutamine supplementation. Based on the current lit-
erature and the findings of this study, clinicians
should consider the holistic profile of the patient, in-
cluding the patient condition and other biomarkers
(e.g., CRP) when selecting patients for glutamine sup-
plementation. This research further contribute base-
line measurements for a larger follow up study
investigating the plasma glutamine levels of ICU pa-
tients at different time points during ICU stay and
comparing them to patient outcome.
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